Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone, Matthew J. Frigault, Naomi Serling‐Boyd, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 24, pp. 2333-2344
Open Access | Times Cited: 1311

Showing 1-25 of 1311 citing articles:

Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Cytokine Storm
David C. Fajgenbaum, Carl H. June
New England Journal of Medicine (2020) Vol. 383, Iss. 23, pp. 2255-2273
Open Access | Times Cited: 2448
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony Gordon, Paul Mouncey, Farah Al-Beidh, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 16, pp. 1491-1502
Open Access | Times Cited: 1733
Severe Covid-19
David Berlin, Roy M. Gulick, Fernando J. Martínez
New England Journal of Medicine (2020) Vol. 383, Iss. 25, pp. 2451-2460
Closed Access | Times Cited: 1390
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama, Jian Han, Linda Yau, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 1, pp. 20-30
Open Access | Times Cited: 1173
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10285, pp. 1637-1645
Open Access | Times Cited: 1016
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
Romina Libster, Gonzalo Pérez Marc, Diego Wappner, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 7, pp. 610-618
Open Access | Times Cited: 858
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
COVID-19 and the human innate immune system
Joachim L. Schultze, Anna C. Aschenbrenner
Cell (2021) Vol. 184, Iss. 7, pp. 1671-1692
Open Access | Times Cited: 661
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Peré Domingo, Isabel Mur, Gràcia Mateo, et al.
JAMA (2021) Vol. 326, Iss. 6, pp. 499-499
Open Access | Times Cited: 600
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 605-612
Open Access | Times Cited: 531
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Betty Raman, David A. Bluemke, Thomas F. Lüscher, et al.
European Heart Journal (2022) Vol. 43, Iss. 11, pp. 1157-1172
Open Access | Times Cited: 526
The signal pathways and treatment of cytokine storm in COVID-19
Lan Yang, Xueru Xie, Zikun Tu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 498
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou, Garyphallia Poulakou, Haralampos Milionis, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1752-1760
Open Access | Times Cited: 451
COVID-19 infection: an overview on cytokine storm and related interventions
Soheila Montazersaheb, Seyed Mahdi Hosseiniyan Khatibi, Mohammad Saeid Hejazi, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 441
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Patrícia O. Guimarães, Daniel Quirk, Remo Furtado, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 5, pp. 406-415
Open Access | Times Cited: 407
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2
Lauren A. Henderson, Scott W. Canna, Kevin G. Friedman, et al.
Arthritis & Rheumatology (2020) Vol. 73, Iss. 4
Open Access | Times Cited: 399
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Viviane Cordeiro Veiga, João Antônio Gonçalves Garreta Prats, Danielle Leão Cordeiro de Farias, et al.
BMJ (2021), pp. n84-n84
Open Access | Times Cited: 382
Severe covid-19 pneumonia: pathogenesis and clinical management
Amy Attaway, Rachel G. Scheraga, Adarsh Bhimraj, et al.
BMJ (2021), pp. n436-n436
Open Access | Times Cited: 366
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
Laura Montefusco, Moufida Ben Nasr, Francesca D’Addio, et al.
Nature Metabolism (2021) Vol. 3, Iss. 6, pp. 774-785
Open Access | Times Cited: 356
T cell response to SARS-CoV-2 infection in humans: A systematic review
Madhumita Shrotri, May C I van Schalkwyk, Nathan Post, et al.
PLoS ONE (2021) Vol. 16, Iss. 1, pp. e0245532-e0245532
Open Access | Times Cited: 351
COVID-19 and Cardiovascular Disease
Mina K. Chung, David A. Zidar, Michael R. Bristow, et al.
Circulation Research (2021) Vol. 128, Iss. 8, pp. 1214-1236
Open Access | Times Cited: 346
Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia
André Santa Cruz, Ana Mendes‐Frias, Ana Andrade Oliveira, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 316
COVID-19: breaking down a global health crisis
Saad I. Mallah, Omar Ghorab, Sabrina Al-Salmi, et al.
Annals of Clinical Microbiology and Antimicrobials (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 305
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Peter Horby, Guilherme Pessoa-Amorim, Leon Peto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 302
Page 1 - Next Page

Scroll to top